Skip to content
Medical Health Aged Care

Avania Buys Spanish MedTech CRO Anagram to Enhance Its Core CRO Offering in a New European Geography

Avania 2 mins read

With Full Suite of Customizable Solutions, Avania Is Taking Industry Lead in Offering Targeted, Actionable Strategies for Medical Devices and Diagnostics in All Major Global Markets


BILTHOVEN, Netherlands--BUSINESS WIRE--

Avania, the leading, global medical technology contract research organization (CRO) and advisory services partner, today announced its acquisition of Anagram. Headquartered in Barcelona, Spain, Anagram is one of the leading MedTech CROs in the Iberian Peninsula, providing MedTech solutions to its customers in Spain, the wider European market, and beyond.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008530546/en/

Avania, the leading, global medical technology contract research organization and advisory services partner, announces its acquisition of Anagram. (Graphic: Business Wire)

Avania, the leading, global medical technology contract research organization and advisory services partner, announces its acquisition of Anagram. (Graphic: Business Wire)

Founded in 1998, Anagram delivers a full service CRO model to their customers including diagnostic imaging core lab (centralized quality control and central assessment of images in clinical trials) services. It is focused on cardiology, oncology, and neurology therapeutic areas. They conduct studies in the U.S., U.K., Spain, Netherlands, France, Germany, and more.

Anagram is a perfect fit for Avania, enabling the company to increase CRO business in Spain and providing greater access to a growing MedTech country. The addition will support cross-sell opportunity by adding scale and will eliminate reliance on current outsourcing partners. Avania customers will benefit from an expanded geographic footprint and an enhanced roster of subject matter experts concentrated on areas of key therapeutic expertise.

“The addition of Anagram furthers our vision of becoming a trusted global partner for the MedTech community, advancing innovations from bench to bedside and improving patient outcomes globally,” said Jason Monteleone, president and CEO of Avania. “It will provide us with a significant footprint in Spain and Southern Europe and further strengthen our cardiovascular and neurology franchises while expanding our oncology capabilities.”

About Avania

Avania is the leading global MedTech clinical research organization and advisory partner with a focus on medical devices, diagnostics/IVDs, and digital health. Core offerings include full service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. When you need to advance your medical technology, It Takes Avania.

About Anagram

Anagram is a Clinical Research Organization (CRO) based in Spain providing high quality services in clinical development and post-authorization trials for drugs and medical devices. Services include image central reading (core lab), analysis, and reporting by highly experienced professionals. Anagram has specialized expertise in cardiology, neurology, and oncology.


Contact details:

Holli Kroeker
+1 308 338 2358
pr@scorrmarketing.com

Jasmine Saba
+1 214 418 3201
jasmine.saba@avaniaclinical.com

Media

More from this category

  • Medical Health Aged Care
  • 26/10/2024
  • 01:10
Rigaku Holdings Corporation

Listing on the Tokyo Stock Exchange Prime Market

TOKYO--BUSINESS WIRE-- Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; "Rigaku"), has completed its listing on the Tokyo Stock Exchange Prime Market as of today. Note: This document is a press release intended for public announcement regarding Rigaku's listing on the Tokyo Stock Exchange Prime Market. It has not been prepared for the purpose of soliciting investments or any similar acts, whether within or outside Japan. This press release does not constitute an offer or sale of securities in the United States. The shares of common stock of Rigaku may…

  • Medical Health Aged Care
  • 25/10/2024
  • 16:11
Galderma

Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

Galderma convenes a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region (JPAC), which will be the largest to…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 25/10/2024
  • 11:30
House of Representatives

Alcohol and other drug health hearings begin

The House of RepresentativesStanding Committee on Health, Aged Care and Sportwill convene a series of public hearings next week in support of itsinquiry into the health impacts of alcohol and other drugs in Australia. The hearings will be held in Melbourne on 28 and 29 October, and in Brisbane on 30 October 2024. Committee Chair,Dr Mike Freelander MP, said that the inquiry had attracted significant public interest since commencing in August. ‘The Committee has received a large number of written submissions highlighting several crucial issues, including the stigma preventing early intervention, links between substance use and domestic violence, and opportunities…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.